# Index

[Index 1](#_Toc515951272)

[List of related documents 4](#_Toc515951273)

[Administrative information 5](#_Toc515951274)

[Title 5](#_Toc515951275)

[Trial registration 5](#_Toc515951276)

[Protocol version 5](#_Toc515951277)

[Funding 5](#_Toc515951278)

[Roles and responsibilities 5](#_Toc515951279)

[Introduction 7](#_Toc515951280)

[Background and rationale 7](#_Toc515951281)

[Objectives 8](#_Toc515951282)

[Trial design 9](#_Toc515951283)

[Methods: Participants, interventions, and outcomes 9](#_Toc515951284)

[Study setting 9](#_Toc515951285)

[Eligibility criteria 9](#_Toc515951286)

[Interventions 9](#_Toc515951287)

[Outcomes 10](#_Toc515951288)

[Participant timeline 11](#_Toc515951289)

[Sample size 12](#_Toc515951290)

[Recruitment 12](#_Toc515951291)

[Methods: Assignment of interventions 12](#_Toc515951292)

[Allocation: sequence generation 12](#_Toc515951293)

[Allocation concealment mechanism 12](#_Toc515951294)

[Implementation 13](#_Toc515951295)

[Methods: Data collection, management, and analysis 13](#_Toc515951296)

[Data collection methods 13](#_Toc515951297)

[Data Management 16](#_Toc515951298)

[Statistical methods 16](#_Toc515951299)

[Methods: Monitoring 16](#_Toc515951300)

[Data monitoring 16](#_Toc515951301)

[Harms 17](#_Toc515951302)

[Auditing 17](#_Toc515951303)

[Ethics and dissemination 17](#_Toc515951304)

[Research ethics approval 17](#_Toc515951305)

[Protocol amendments 17](#_Toc515951306)

[Consent and assent 17](#_Toc515951307)

[Confidentiality 18](#_Toc515951308)

[Declaration of interests 18](#_Toc515951309)

[Access to data 18](#_Toc515951310)

[Ancillary and post-trial care 18](#_Toc515951311)

[Dissemination policy 18](#_Toc515951312)

[References 19](#_Toc515951313)

List of abbreviations

|  |  |
| --- | --- |
| AE | Adverse Event |
| cACT | Childhood Asthma Control Test |
| COHb | Carboxyhaemoglobin |
| COMREC | College of Medicine Research Ethics Committee |
| DSMB | Data and Safety Monitoring Board |
| FeNO | Fractionally exhaled nitric oxide |
| FEV1 | Forced Expiratory Volume in 1 second |
| FVC | Forced Vital Capacity |
| GCP | Good Clinical Practice |
| GINA | Global Initiative for Asthma |
| HFA-BDP | Beclomethasone diproprionate, with hydrofluoroalkane-134a propellant |
| ICS | Inhaled corticosteroid e.g. Beclomethasone |
| LIC | Low Income Country |
| LSTM | Liverpool School of Tropical Medicine |
| MLW | Malawi-Liverpool-Wellcome Trust Clinical Research Programme |
| MUAC | Mid-upper arm circumference |
| PACTR | Pan African Clinical Trials Registry |
| PI | Principal Investigator |
| QECH | Queen Elizabeth Central Hospital |
| RCT | Randomised Controlled Trial |
| SABA | Short acting β2-agonist e.g. Salbutamol |
| SAE | Serious Adverse Event |

# List of related documents

|  |  |
| --- | --- |
| Appendix |  |
| 1 | Study flowchart v2.2 |
| 2 | Study information sheet v2.4 – English |
| 3 | Study information sheet v2.4 - Chichewa |
| 4 | Consent form v2.4 – English |
| 5 | Consent form v2.4 - Chichewa |
| 6 | Screening questionnaire v2.2 – combined English/Chichewa |
| 7 | Baseline questionnaire v2.2 – combined English/Chichewa |
| 8 | Review questionnaire v2.2 – combined English/Chichewa |
| 9 | Childhood Asthma Control Test (cACT) v2.2 – English |
| 10 | Childhood Asthma Control Test (cACT) v2.2 - Chichewa |
| 11 | Asthma education session outline v2.2 |
| 12 | Assent form v1.1 – English |
| 13 | Assent form v1.1 – Chichewa |
| 14 | Study information sheet\_Child v1.1 – English |
| 15 | Study information sheet\_Child v1.1 - Chichewa |
| 16 | Focus group discussions Topic Guide v1 |

# Administrative information

# Title

A randomised controlled trial of an enhanced asthma care package vs standard outpatient care on asthma control in Malawian children.

Short title; Phenotyping Asthmatic Children [PAC study]

# Trial registration

Pan African Clinical Trials Registry: PACTR201807211617031

# Protocol version

V3.1, 02/04/2019

# Funding

Medical Research Council: Doctoral Training Programme at LSTM

National Institute for Health Research: Global Health Research Unit on Lung Health and Tuberculosis in Africa at LSTM

# Roles and responsibilities

## Investigators

Principal investigator

**Dr Sarah Rylance**; Consultant Paediatrician, Queen Elizabeth Central Hospital, Blantyre, Malawi

PhD student, Liverpool School of Tropical Medicine, UK;

Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi

BMBS, BMed Sci, MRCPCH, DTM&H, MRes

Co-investigators / PhD supervisors

**Dr Kevin Mortimer**, Reader, Liverpool School of Tropical Medicine (Co-Principal Investigator)

Lecturer, College of Medicine, Malawi

BA, MA, MB BChir, FRCP, DTM&H, MSc, PhD

**Prof Jonathan Grigg**; Professor in Paediatric Respiratory and Environmental Medicine, Queen Mary University of London (Co-Investigator)

BSc, MB BS, MD, MRCP, FRCPCH

**Dr. Chris Jewell**; Senior Lecturer in Epidemiology, CHICAS, Lancaster University (Co-Investigator)

BSc, BVSc, MSc, PhD

**Dr. Kondwani Jambo;** Wellcome Trust Intermediate Fellow, Malawi-Liverpool-Wellcome Trust Clinical Research Programme (Co-investigator)

BSc, MSc, PhD

## Trial sponsor

Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA.

Contact: Carl Henry, Research Governance Manager

Carl.Henry@lstmed.ac.uuk

# Introduction

# Background and rationale

Asthma is the most common chronic condition in childhood and an emerging health problem in Africa 1. However, the burden of chronic respiratory symptoms in sub-Saharan Africa is poorly described. Limited data from urban populations estimate the prevalence of “current wheeze” at 14-20% among older children, and 5-13% in younger children, with severe asthma symptoms in over half of those reporting wheeze 2,3. In Queen Elizabeth Central Hospital (QECH) in Malawi, children frequently attend emergency care with acute wheeze, with severe cases admitted for nebulisers and intravenous bronchodilators. Children with chronic wheeze account for approximately one-third of children followed-up in the general paediatric clinic, alongside a wide variety of other medical conditions. Due to the busy, unstructured nature of this clinic, and ad-hoc attendance of patients, it is challenging for clinicians to perform a thorough clinical assessment and monitor treatment response adequately.

It is now widely acknowledged that the diagnosis of “asthma” encompasses a spectrum of lower airway diseases, with diverse underlying pathophysiology 4. Sputum inflammatory phenotypes; eosinophilic, neutrophilic, mixed or paucigranulocytic, may be useful in guiding therapy, and this approach has been explored in the context of severe asthma in high-income countries 5. However, to date there are no data regarding airway inflammatory phenotypes in wheezy children in low-income countries (LIC). Research from Brazil, a middle-income country, classified the majority of asthmatic children as non-atopic6, with predominantly neutrophilic airway inflammation seen in this group, compared to eosinophilic airway inflammation seen in atopic asthmatics7.

Several factors may influence the development of asthma and underlying pathophysiological processes, in the low-income setting; low birth weight 8, early viral infections (RSV, rhinovirus) 9, household air pollution (HAP) 10, nutrition 11. Greater exposure to microbes, endotoxin and farm animals may have a protective effect 12. The role of helminth infections in atopy and asthma remains unclear 13,14.

The long-term goals of asthma management are to achieve good symptom control and minimize future risk of adverse outcomes (exacerbations, fixed airflow limitation and side-effects of treatment) 15. Current global treatment guidelines, focusing on inhaled corticosteroids (ICS), are extrapolated from high-income settings 15. These guidelines are appropriate where steroid-responsive, allergen-driven, eosinophilic asthma predominates. If the pathophysiology underlying wheeze in LIC is different, current recommended treatments may be ineffective or even harmful, particularly in the context of a high burden of TB and other opportunistic infections 16. It is plausible that alternative treatments such as macrolide antibiotics or theophylline may be more appropriate.

In high-income settings, asthma education is considered an essential component of asthma therapy, leading to decreased emergency visits and hospital admissions 17,18, however there are no data relating to LIC. Similarly, there is very limited research on long-term asthma treatment outcomes in LIC. A study of adults from six LIC reported improved asthma control at one-year in one-third of patients, but suffered from a high rate of defaulters 19.

There is a lack of research exploring asthma-related morbidity in sub-Saharan Africa, particularly in children. The burden of asthma symptoms and exacerbations is poorly defined, and it is unclear whether asthmatic children in this setting respond to globally advocated treatment. The piloted intervention will include the components of global treatment guidelines that are feasible and potentially scalable in Malawi, at the present time. If effective, the delivery of asthma education by non-medical staff would be an attractive, pragmatic approach in low-income settings.

We will describe the levels of symptom control, exacerbation rates and response to treatment in a large cohort of asthmatic Malawian children – this is essential to inform future research in this clinical area.

This research will be the first to establish airway inflammatory phenotype in children with asthma, from a LIC. Greater understanding of the underling pathophysiology will help to direct appropriate clinical treatment. Identification of characteristics associated with poor asthma control may highlight potentially modifiable exposures or suggest areas to focus treatment.

# Objectives

In a cohort of Malawian children, aged 6-15 years, with doctor-diagnosed asthma, the specific objectives are

* To evaluate the effect of a package of enhanced asthma care (clinical and spirometric assessment, individualised asthma education, and optimisation of inhaled treatment) on asthma control and exacerbations, over a 3-month period
* To describe the prevalent clinical phenotypes, defined by asthma symptoms, exacerbating factors, spirometric abnormality, and response to treatment
* To determine the proportion of asthmatic children with eosinophilic airway inflammation
  + defined as ≥2.5% eosinophils/total sputum cell count
  + defined as FeNO (Fractional exhaled Nitric Oxide) > 20ppb (parts per billion)
* To identify clinical and laboratory features predictive of poor response to optimised asthma treatment
* To explore the effect of household air pollution on asthma control, using exposure biomarkers; carboxyhaemoglobin and alveolar macrophage carbon loading

# Trial design

This is a pilot randomised controlled trial of standard vs enhanced asthma care, in a cohort of children attending outpatient follow-up. Additionally, we will use clinical and laboratory methods to describe the phenotypes of asthmatic children in Malawi, and identify factors predictive of poor asthma control.

# Methods: Participants, interventions, and outcomes

# Study setting

Participants will be recruited from the General Paediatric clinic at Queen Elizabeth Central Hospital (QECH), in Blantyre. QECH is a 1100-bedded tertiary care, general government hospital serving the southern region of Malawi. In 2016, approximately 26,000 children (aged <16 years) were admitted to the paediatric department, with a further 65,000 children treated without admission 20. Children are referred to the weekly General Paediatric clinic from local health centres and the QECH Paediatric Emergency Department, and following hospital admission.

# Eligibility criteria

**Inclusion criteria;** all assenting children aged 6-15 years attending the QECH paediatric general clinic with doctor-diagnosed “asthma” will be eligible.

**Exclusion criteria;** children receiving TB treatment or those with symptoms suggestive of TB (fever, night sweats, haemoptysis, weight loss) will be excluded from the study. Children identified with symptoms suggestive of TB at screening, will be referred to the paediatric TB clinic at QECH, for further assessment and management.

The detailed assessment will be postponed for patients who are acutely unwell, or currently receiving oral corticosteroids, or with a recent respiratory infection or asthma exacerbation (within past 4-weeks). Children with contraindications to spirometry (chest or abdominal pain, haemoptysis) will be excluded from spirometry, sputum induction and exercise challenge, but may participate in all other aspects of the study.

# Interventions

## RCT design: control group

Children will receive standard care in the general paediatric clinic at QECH. SABA (e.g. salbutamol) and corticosteroid (eg. beclomethasone diproprionate (HFA-BDP)) inhalers are included in the Malawi Standard Treatment Guidelines, and usually available, free of charge, in the hospital pharmacy. Dose adjustment of inhaled treatment, patient education and follow-up interval are at the discretion of the reviewing clinician (a Paediatric registrar or Consultant).

## RCT design: intervention group

Families will receive an individual asthma education session from a specifically trained fieldworker (non-medical). Following a detailed clinical assessment, ICS treatment will be escalated in those children defined as having poor asthma control (cACT score ≤19), in line with global asthma guidelines 15. This subgroup of patients will be reviewed at 6-weeks, for repeated asthma education and to assess their response to treatment and treatment adherence.

Asthma education session

Studies demonstrating a beneficial impact of asthma education in HIC include a wide range of interventions, with variable content, duration and delivery methods 17,18. The pilot intervention is designed to be feasible and scalable in this setting, if benefit is demonstrated. A 1-hour individualised asthma education session for the child and carer will be delivered by trained fieldworkers (non-medical), with oversight by a doctor (study PI) or study nurse. Before study initiation, fieldworkers will complete a structured training programme, with accompanying training manual, and will compete an assessment their knowledge and skills. Each asthma education session will follow a structured approach, with checklist (*see appendix 11*), to ensure intra- and inter-fieldworker consistency. Patients will be given a written asthma action plan - these facilitate the early detection and treatment of an exacerbation, and have been shown to improve asthma health outcomes in HIC 21.

Optimisation of ICS treatment

Inhaled beclomethasone diproprionate, formulated with hydrofluoroalkane-134a (HFA-BDP) propellant is widely accepted as a highly effective, well tolerated asthma treatment, in both adults and children 22. Children randomised to enhanced care, with poor asthma control, will receive 200µg twice daily of HFA-BDP, via a home-made bottle spacer – in keeping with evidence that moderate doses of ICS (200-400 µg/day) appear more effective than initial low doses (<200 µg/day), with little additional benefit but greater side effects seen at higher doses (>400 µg/day) 23. Those with good control will continue their existing dose of ICS. All children will receive inhaled SABA as needed, via a home-made bottle spacer.

***Qualitative analysis of the the acceptability and perceived value of the asthma education sessions*** Following completion of the intervention, a purposively selected sample of carers, children and field workers will be invited to take part in qualitative work that will seek to analyse the perceived value and acceptability of the asthma education sessions provided within the RCT’s intervention. We will seek additional verbal consent and assent for the participants to join in focus group meetings or semi structured interviews. The data will be analysed to describe the experiences of the field workers, children and carers, relating to the asthma education sessions, outline the perceived value of the sessions to the children and the carers, identify any barriers and facilitators to information delivery or uptake and suggest areas for improvement within the education sessions

# Outcomes

International guidelines recommend a multicomponent assessment of asthma outcomes in clinical trials, with measures reflecting symptom control and future risk of adverse outcomes 24. The primary outcome has been chosen to reflect disease control within the intervention. This standardised measure will allow clinically significant improvements in patient well-being to be detected (see *Sample size*).

## Primary outcome

* Composite score of current clinical control – measured by cACT 25,26, translated into Chichewa

## Secondary outcomes

* Exacerbations requiring hospitalization
* Exacerbations requiring emergency (unscheduled) health care use
* Exacerbations requiring systemic (oral) corticosteroid use for ≥3 days
* Days absent from school
* Lung function (pre- and post-bronchodilator FEV1)
* Fractional concentration of exhaled nitric oxide (FeNO)

Assessment of asthma control, treatment and exacerbations will be assessed by questionnaire at baseline, and 3-months for all participants. Beyond the study period, the cohort will continue follow-up in the general clinic, with monitoring of asthma control as part of routine clinical care.

# Participant timeline

Participants will be recruited during their routine attendance at the paediatric general clinic. Following informed consent, participants will complete the baseline questionnaire, including the cACT. Children will be stratified by baseline level of asthma control, defined by cACT score (≥20 or ≤19). Those in the intervention arm will attend for a study visit shortly after recruitment, and a further visit at 6-weeks if they have poor control (cACT ≤19 or abnormal spirometry) at the study visit.

All participants will be followed-up after 3-months.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Baseline screening, consent and randomisation – in clinic | *Month 1* | *Month 2* | *Month 3* | Review asthma control at 3 months – study visit | *After 3-month trial protocol completed* |
| **Enhanced care**  Including study assessment  + 6-week review if poor control | | | Return to monitoring in general clinic |
| **Standard care** | | | Optional assessment visit  + 6-week review if poor control |

Figure 1: Study schedule for a child recruited and randomised to initially receive either enhanced care (top row) or standard care (bott om row).

# Sample size

Evidence on which to estimate the level of asthma control is lacking for children in this setting, however poor asthma control is reported in 57% of adults in Nigeria27 and 83% of adults in Uganda28, with a mean ACT score of 17 (SD5) in the Nigerian cohort.

A sample of 90 children should be sufficient, to detect a clinically meaningful difference in the primary outcome; asthma control measured by cACT. Using a two-tailed T-test, with the null hypothesis that there is no difference in mean ACT score between groups after receiving 3-months of enhanced vs standard asthma care, 45 children in each group, should detect a difference in ACT of 3 (0.6SD), with 80% power, at a 5% significance level 29.

In addition to the hypothesis-driven RCT treatment-effect analysis, we will conduct an exploratory analysis of pre-defined variables (sputum eosinophils, FeNO, adherence) contributing to asthma control and response to treatment.

The proposed target of 120 children, makes allowance for loss-to-follow-up, and difficulty in obtaining acceptable spirometry in this age group (success rate ~ 70% in a similar population 30).

# Recruitment

Given current estimates of asthmatic children attending the general paediatric clinic, we expect to recruit 120 children over a 4-6-month period. Participation rates are likely to be high, since the children and their families will appreciate the opportunity for clinical assessment and education, which is not possible in the clinic setting at present.

# Methods: Assignment of interventions

# Allocation: sequence generation

Random number sequences will be computer-generated, with variable, random length, permuted blocks. Separate sequences will be generated for stratified allocation based on baseline cACT ≥20 or ≤19.

# Allocation concealment mechanism

Sequential participant ID numbers will be allocated (from the relevant stratum), with study group allocation derived from a concealed file which is accessible only during electronic questionnaire completion.

# Implementation

The allocation sequence will be generated by an independent statistician. Participant ID stickers with unique identifying, pre-printed bar-codes will be used, to minimise data entry errors. The look-up file, containing the random number sequence, will be concealed from the study staff.

# Methods: Data collection, management, and analysis

# Data collection methods

Screening, enrolment and randomisation

Eligibility will be assessed using a short screening questionnaire (*see appendix 6*), for all children attending the general paediatric clinic with a diagnosis of asthma. Following informed consent, the baseline questionnaire will be completed for all participants, to inform stratified randomisation, based on cACT (score ≥20 or ≤19).

Study visits

The table below summarises the clinical data that will be collected during study visits;

|  |  |  |
| --- | --- | --- |
| **Assessment** | **6-week review**  **For poor control subgroup** | **3-month review** |
| Review questionnaire  Physical examination  Height, weight, MUAC  FeNO  Spirometry  Sputum induction  Exercise challenge  COHb measurement  CXR if clinically indicated | Review questionnaire Adherence assessment | Review questionnaire  FeNO  Spirometry |

MUAC, mid-upper arm circumference; FeNO, fractionally exhaled nitric oxide; COHb, carboxyhaemoglobin; CXR, chest x-ray

Data collected during routine clinical monitoring in the paediatric clinic for the 3 months following completion of the trial, will maximise follow-up experience of the enhanced package, providing insight into participants’ asthma control over a longer timeframe.

Clinical methods

Questionnaires (electronic)

Questionnaires will be administered in Chichewa, by a fieldworker and responses entered onto an electronic data capture form (KoBoToolbox31).

The baseline questionnaire (*see appendix 7*) includes current asthma symptom control (using the cACT25 and GINA criteria15), current treatment, recent exacerbations, previous medical history (including HIV status if known), past asthma exacerbations and health care use, potential contributing factors, asthma triggers and activity levels.

The review questionnaire (*see appendix 8*), administered at the assessment visit, 6-weeks (if indicated), and 3-month follow-up, details current asthma symptom control (using the cACT25 and GINA criteria15), current treatment, and recent exacerbations.

cACT

The cACT is a 7-item validated questionnaire 25,26, which has been translated into Chichewa according to linguistic validation guidelines 32 – *see appendices 9 and 10*. This process has included forward and back translation, and patient testing. The copyright holder has granted permission for the paper questionnaire to be administered by a fieldworker, rather than self-completed by the child/parent.

***Physical examination***

The PI (a Consultant Paediatrician) will examine each participant. Growth monitoring (height, weight and mid-upper arm circumference (MUAC)) will be performed by a fieldworker or nurse.

Spirometry

Spirometry will be conducted by a trained and experienced technician, using an Easy On-PC spirometer (ndd Medical Technologies), according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines 33. Lung function will be measured before and after a 400µg dose of Salbutamol administered by meter-dose inhaler via a Volumatic spacer. Lung function parameters; forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and bronchodilator responsiveness, will be interpreted with reference to the Global Lung Initiative 2012 equations 34.

Exhaled nitric oxide (FeNO)

FeNO is a non-invasive method used to identify eosinophilic airway inflammation. Participants will be asked to exhale into a NObreath machine (Bedford Scientific Ltd.) for 10 seconds as per ATS/ERS guidelines 35

Carboxyhaemoglobin (COHb) measurement

COHb is measured non-invasively using a Rad-57 Pulse CO-Oximeter (Masimo Corporation). The measurement is taken from a finger-clip, which is worn for approximately one minute and has been well-tolerated by ~3000 Malawian children involved in recent research studies.

***Chest X-ray (CXR)***

Patients with symptoms or spirometric abnormalities suggesting an alternative (non-asthma) pathology will undergo a CXR.

Induced sputum sampling

Will be performed by a trained fieldworker/nurse according to a standard method. Sputum will be collected following sequential 5-minute inhalation periods of nebulised 4.5% saline, to a maximum of 20-minutes. Lung function will be monitored during the procedure to detect clinically significant bronchoconstriction, although the procedure is extremely well tolerated in children, even those with severe asthma 36.

Exercise challenge

Participants will be asked to run, on the flat, with maximum effort for a period of 6 minutes, according to a standardised protocol 37. Effort will be assessed at the end of exercising, by submaximal heart-rate, which should be >170 beats per minute. Following this, lung function will be monitored at 5, 10 and 15-minute intervals.

Adherence assessment

Those participants with initial poor control will attend an additional study visit at 6-weeks, during which adherence to inhaled corticosteroid medication will be assessed, by weighing the metered-dose inhaler (MDI) canisters on a digital electronic 0.01-gram precision scale. By calculating the weight of each MDI discharge, and recording canister weight change over a defined period (6-weeks), the actual number of discharges can be divided by the prescribed number of discharges, to give the percent prescribed taken.38

Laboratory methods

Sputum cytology will be assessed using light microscopy and flow cytometry39,40, to determine the total and differential cell count, % eosinophils, and % neutrophils.

Alveolar macrophage carbon loading analysis using light microscopy, digital imaging and calculation of carbon-black area using ImageJ software41

**Qualitative methods**

A purposively selected sample of carers, children and fieldworkers will be invited to take part in qualitative work that will seek to analyse the perceived value and acceptability of the asthma education sessions provided within the RCT’s intervention. The participants will be invited to participate in focus group meetings or semi structured interviews to describe their experiences with the asthma education sessions. The data collected in these meetings will be non-sensitive information (see topic guide appendix 16).

# Data Management

Each patient attending the detailed clinical assessment, will have a personal clinical record stored in a confidential asthma clinic file. This will be kept in a secure clinical location and will facilitate feedback of the assessment results to the child and the clinic staff.

Electronic questionnaire data will be collected using KoBoToolbox31. Data will be stored securely on the MLW server, in Microsoft Excel format, for subsequent analysis using R software42. All electronic data will be anonymised, with a unique patient number assigned to each participant. Patient contact details (address and phone number), will be stored in a separate, password protected spreadsheet.

# Statistical methods

The primary outcome, response to treatment, will be reported as a scalar variable, defined by cACT score. Differences between participants in the intervention and control arms will be assessed using Student’s t-tests. To measure change in cACT over time, final measurements will be compared, with adjustment for baseline measurement and intervention, as covariates in a regression model. Participant data will be primarily analysed by intention-to-treat, although per-protocol analysis will also be performed. Secondary outcomes will include; asthma exacerbations requiring hospitalization or unscheduled health-care attendance, missed school days, use of oral steroids, lung function and FeNO. The contribution of pre-specified explanatory variables; sputum eosinophilia, FeNO level and treatment adherence, will be assessed using multivariable linear regression using paired ACT measurements from participants (at the start and end of “enhanced care”).

The cohort will be described, in terms of proportions of patients demonstrating specific clinical and airway inflammatory phenotypes. Clinical phenotypes will be described by; atopic features, age at asthma onset, asthma triggers (including exercise), lung function, bronchial hyperresponsiveness 43. Airway inflammation will be categorised as eosinophilic or non-eosinophilic based on induced sputum cytology (≥2.5% vs <2.5% eosinophils/total sputum cell count respectively), and on the basis of FeNO results (low <20 ppb, intermediate 20-35 ppb, high >35ppb)44.

**Qualitative analysis**

The experiences of key informants (patients, their carers and the study staff) will be sought through focus-group discussions and individual semi-structured interviews. We will use purposive sampling to ensure that key participant characteristics are represented; e.g. age, sex, asthma severity, and to ensure diversity of views from the participants. Thematic analysis of anonymised transcripts will be performed concurrently with the data collection process and will continue until saturation is reached. We will adopt an interpretive phenomenological approach, to identify emerging themes and sub-themes through an iterative process. Further analysis will identify strengths, limitations and areas for improvement for future development of the intervention.

# Methods: Monitoring

# Data monitoring

Although the intervention is novel in this low-income setting, it is considered standard practice throughout high-income countries, and is therefore considered to be low-risk, with serious adverse events, unlikely to be related to the intervention (clinical assessment, inhaled medication and patient education). Due to the nature of the disease being studied, it is likely that some children will attend or be admitted to hospital for asthma exacerbations during the study period. A Data and Safety Monitoring Board (DSMB) will safeguard the welfare of trial participants and discuss safety reporting (at approximately 2-months) to ensure the safety of offering “enhanced care” to those initially randomised to standard care, for a 3-month post allocation period. The proposed DSMB (to be agreed by the trial sponsor) will comprise; a senior biostatistician, a Consultant Paediatrician with clinical experience in Malawi, and a Consultant academic physician with RCT experience in LIC. The DSMB charter will be stored in the trial master file and investigator site file.

# Harms

Serious Adverse Events (SAEs) will be recorded, including events which; result in death, are life-threatening, require hospitalisation, result in disability, require intervention to prevent permanent impairment 45. All SAEs will be reported to the DSMB within 72-hours of their first notification, and the sponsor will be informed if the event is thought to be intervention related. The DSMB will receive a monthly summary of all SAEs. Parents will be asked to contact the study team if their child is admitted to hospital during the study period, and where possible the child will be reviewed by a member of the study team during the admission, to collect relevant details. If this is not possible, relevant information will be collected through a follow-up phone call. Information relating to adverse events, specifically health-care attendance not requiring hospitalization will also be collected.

# Auditing

Study initiation, interim monitoring and close-out will be overseen by the Clinical Research Support Unit (CRSU) at MLW.

# Ethics and dissemination

# Research ethics approval

The study has approval from the College of Medicine Research Ethics Committee (COMREC) in Malawi (P.04/18/2384) and LSTM Research Ethics Committee (REC), in the UK (research protocol 18-018).

# Protocol amendments

The PI is responsible for communicating any major protocol modifications to all co-investigators, the DSMB, COMREC and LSTM REC, the trial sponsor, and PACTR.

# Consent and assent

Written informed assent and consent will be obtained from the child and their parent/ guardian following a detailed explanation of study procedures, and provision of a Participant Information Sheet in Chichewa or English – *see appendices 2 and 3*. The Participant Information Sheet, follows the University of Malawi College of Medicine template, and will be read out to all participants to facilitate discussion and ensure that inability to read is not an obstacle to participation.

A mark witnessed by someone independent to the study will be accepted where participants are unable to sign.

Children will be actively involved in the explanation of study procedures, and will only be included if they also agree to participate. Children will be provided with a child-friendly version of the study information sheet.

# Confidentiality

All data stored in the trial database will be anonymised and identified by a unique participant ID number. Contact details and a clinical record for each participant will be kept confidentially in a clinic file, stored in a locked filing cabinet. Data will be backed up to a study folder on the MLW server, with access granted only to the PI and data manager.

# Declaration of interests

The investigators have no financial or competing interests

# Access to data

Following publication, the final anonymised data set will be archived in an open-access data repository, facilitated by LSTM.

# Ancillary and post-trial care

Participants allocated to the control arm for the initial 3-months, will be offered the option to enter the intervention arm, after the 3-month randomisation period is complete. All participants will continue to be follow-up in the paediatric general clinic at the end of the study period.

# Dissemination policy

The study findings will be presented at local and international conferences and published in peer-reviewed journals with open access. We will present our findings at the College of Medicine research dissemination conference. A copy of the final report, published papers and conference abstracts will be submitted to; the College of Medicine Research and Ethics Committee, the College of Medicine Library, the Health Sciences Research Committee, the University Research and Publication Committee.

We will also ensure there is feedback of the study findings to the participants and their families.

# References

1. Asher I, Pearce N. Global burden of asthma among children. *Int J Tuberc Lung Dis* 2014; **18**(11): 1269-78.

2. Ait-Khaled N, Odhiambo J, Pearce N, et al. Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: the International Study of Asthma and Allergies in Childhood Phase III. *Allergy* 2007; **62**(3): 247-58.

3. Wa Somwe S, Jumbe-Marsden E, Mateyo K, et al. Improving paediatric asthma care in Zambia. *Bull World Health Organ* 2015; **93**(10): 732-6.

4. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. *Thorax* 2002; **57**(7): 643-8.

5. Bush A, Fleming L. Phenotypes of refractory/severe asthma. *Paediatr Respir Rev* 2011; **12**(3): 177-81.

6. Pereira MU, Sly PD, Pitrez PM, et al. Nonatopic asthma is associated with helminth infections and bronchiolitis in poor children. *Eur Respir J* 2007; **29**(6): 1154-60.

7. Drews AC, Pizzichini MM, Pizzichini E, et al. Neutrophilic airway inflammation is a main feature of induced sputum in nonatopic asthmatic children. *Allergy* 2009; **64**(11): 1597-601.

8. Xu XF, Li YJ, Sheng YJ, Liu JL, Tang LF, Chen ZM. Effect of low birth weight on childhood asthma: a meta-analysis. *BMC Pediatr* 2014; **14**: 275.

9. Busse WW, Lemanske RF, Jr., Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. *Lancet* 2010; **376**(9743): 826-34.

10. Wong GW, Brunekreef B, Ellwood P, et al. Cooking fuels and prevalence of asthma: a global analysis of phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). *Lancet Respir Med* 2013; **1**(5): 386-94.

11. Beasley R, Semprini A, Mitchell EA. Risk factors for asthma: is prevention possible? *Lancet* 2015; **386**(9998): 1075-85.

12. Stein MM, Hrusch CL, Gozdz J, et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. *N Engl J Med* 2016; **375**(5): 411-21.

13. Leonardi-Bee J, Pritchard D, Britton J. Asthma and current intestinal parasite infection: systematic review and meta-analysis. *Am J Respir Crit Care Med* 2006; **174**(5): 514-23.

14. Calvert J, Burney P. Ascaris, atopy, and exercise-induced bronchoconstriction in rural and urban South African children. *J Allergy Clin Immunol* 2010; **125**(1): 100-5 e1-5.

15. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017.

16. Bush A, Kleinert S, Pavord ID. The asthmas in 2015 and beyond: a Lancet Commission. *Lancet* 2015; **385**(9975): 1273-5.

17. Boyd M, Lasserson TJ, McKean MC, Gibson PG, Ducharme FM, Haby M. Interventions for educating children who are at risk of asthma-related emergency department attendance. *Cochrane Database Syst Rev* 2009; (2): CD001290.

18. Coffman JM, Cabana MD, Halpin HA, Yelin EH. Effects of asthma education on children's use of acute care services: a meta-analysis. *Pediatrics* 2008; **121**(3): 575-86.

19. Ait-Khaled N, Enarson DA, Bencharif N, et al. Treatment outcome of asthma after one year follow-up in health centres of several developing countries. *Int J Tuberc Lung Dis* 2006; **10**(8): 911-6.

20. Molyneux EM LJ, Njiram'madzi J, Robertson AM,. Setting up and running a paediatric emergency department in a hospital in Malawi: 15 years on. *BMJ Paediatrics Open* 2017; **1**.

21. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. *Thorax* 2004; **59**(2): 94-9.

22. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. *Cochrane Database Syst Rev* 2005; (1): CD002738.

23. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. *Cochrane Database Syst Rev* 2004; (2): CD004109.

24. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 2009; **180**(1): 59-99.

25. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy Clin Immunol* 2007; **119**(4): 817-25.

26. Liu AH, Zeiger RS, Sorkness CA, et al. The Childhood Asthma Control Test: retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. *J Allergy Clin Immunol* 2010; **126**(2): 267-73, 73 e1.

27. Ozoh OB, Okubadejo NU, Chukwu CC, Bandele EO, Irusen EM. The ACT and the ATAQ are useful surrogates for asthma control in resource-poor countries with inadequate spirometric facilities. *J Asthma* 2012; **49**(10): 1086-91.

28. Serugendo AN, Kirenga BJ, Hawkes M, Nakiyingi L, Worodria W, Okot-Nwang M. Evaluation of asthma control using Global Initiative for Asthma criteria and the Asthma Control Test in Uganda. *Int J Tuberc Lung Dis* 2014; **18**(3): 371-6.

29. Sample size calculator for Student t-tests. <https://www.danielsoper.com/statcalc/calculator.aspx?id=47> (accessed 30/1/18.

30. Kirkby J, Bountziouka V, Lum S, Wade A, Stocks J. Natural variability of lung function in young healthy school children. *Eur Respir J* 2016; **48**(2): 411-9.

31. Harvard Humanitarian Initiative. KoBo Toolbox - open source data collection tool. <http://www.kobotoolbox.org/> (accessed 30/03/2018.

32. Mapi Research Trust. Linguistic Validation Guidance of a Clinical Outcome Assessment (COA). 2016.

33. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005; **26**(2): 319-38.

34. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; **40**(6): 1324-43.

35. American Thoracic S, European Respiratory S. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005; **171**(8): 912-30.

36. Pizzichini E, Pizzichini MM, Leigh R, Djukanovic R, Sterk PJ. Safety of sputum induction. *Eur Respir J Suppl* 2002; **37**: 9s-18s.

37. Haby MM, Anderson SD, Peat JK, Mellis CM, Toelle BG, Woolcock AJ. An exercise challenge protocol for epidemiological studies of asthma in children: comparison with histamine challenge. *Eur Respir J* 1994; **7**(1): 43-9.

38. Rodriguez-Martinez C, Sossa M, C R. Validation of a questionnaire for assessing adherence to metered-dose inhaler use in asthmatic children. *Pediatric Asthma, Allergy and Immunology* 2007; **20**(4): 243-53.

39. Lay JC, Peden DB, Alexis NE. Flow cytometry of sputum: assessing inflammation and immune response elements in the bronchial airways. *Inhal Toxicol* 2011; **23**(7): 392-406.

40. Jochems SP, Piddock K, Rylance J, et al. Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection Compared to Nasal Wash. *PLoS One* 2017; **12**(1): e0169805.

41. Jary H, Rylance J, Patel L, Gordon SB, Mortimer K. Comparison of methods for the analysis of airway macrophage particulate load from induced sputum, a potential biomarker of air pollution exposure. *BMC Pulm Med* 2015; **15**: 137.

42. R Core Team. R: A language and envronment for statistical computing. 3.3.2 ed. Vienna, Austria; 2013.

43. Henderson AJ. Childhood asthma phenotypes in the twenty-first century. *Breathe* 2014; **10**(2): 101-8.

44. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* 2011; **184**(5): 602-15.

45. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting. . 1994.